Spanish HealthTech company Quibim, specialized in AI-powered medical imaging analysis, is entering a new phase of growth. With more than 170 deployments worldwide and major industrial partnerships in place, the company now sets its sights on the United States to strengthen collaborations with hospitals and pharmaceutical players.
Founded in 2012 in Valencia, Quibim develops software solutions that extract imaging biomarkers capable of characterizing an organ, lesion, or disease at an early stage. The company uses artificial intelligence models trained on MRI, CT, and PET data to generate reproducible insights for diagnosis, therapeutic monitoring, and clinical trial recruitment.
Its clinical products, QP-Brain (neurological diseases), QP-Prostate (prostate cancer detection), and QP-Liver (fat and iron quantification in liver tissue)—are already in use across hospitals in Europe and North America. In parallel, the QP-Insights platform, designed for the pharmaceutical industry, manages more than 100 million medical images in the context of clinical trials and multi-omics data integration.
From imaging to digital twins
Quibim is now focusing its efforts on dynamic digital models of the human body, also known as medical digital twins. The goal is to provide individualized predictions of disease progression and simulate treatment responses. These models have already been deployed at the organ level (brain, liver, prostate), with full-body coverage targeted within three years.
This positioning has attracted several major industry players. In 2023, Philips signed a global partnership to integrate Quibim’s algorithms into its MR scanners. The company also collaborates with Merck KGaA and Novartis to improve patient stratification in clinical research.
Strategic move toward the U.S.
Quibim’s next step is to establish a robust commercial and scientific presence in the U.S.. The North American market is key for the Spanish startup due to its advanced clinical infrastructure, high volume of clinical trials, and strong demand for predictive imaging tools among pharmaceutical companies.
€47.9 million Series A to scale operations
To support this expansion, Quibim announced in August 2025 the closing of a €47.9 million Series A round. The round was co-led by ASABYS (via its Sabadell Asabys II fund) and BUENAVISTA EQUITY PARTNERS (via the BHG I fund, in partnership with Columbus Venture Partners). New investors include GoHub Ventures and UI Investissement, joining existing backers such as Amadeus Capital Partners, APEX Ventures, Partech, Adara Ventures, Leadwind (K Fund), Build Collective (Tony Fadell), and Jonathan Milner, founder of Abcam.
This brings Quibim’s total funding to over €50 million since its inception. The company will use the capital to establish operations in the U.S., strengthen its industrial alliances, and accelerate the development of new diagnostic tools based on digital twin technology. AI-enhanced biomedical imaging is entering a phase of industrial-scale deployment.
